Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flortaucipir F18 biodistribution and safety in healthy and cognitively impaired subjects
NCT04474405Phase 1Completed
- Sponsor
- Avid Radiopharmaceuticals
- Start
- Aug 2013
- Primary completion
- Dec 2013
- Countries
- 1
01
Overview
Phase 1, open-label trial (3 arms), sponsored by Avid Radiopharmaceuticals. Primary endpoints: Brain Flortaucipir Uptake and Flortaucipir Whole Body Effective Dose. Started Aug 2013; status: completed.
Beyond the preview
Go deeper on NCT04474405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04474405.